Jenburkt Pharmaceuticals Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Jenburkt Pharmaceuticals Ltd trades at ₹1,128, in a confirmed uptrend and 3 weeks into that stage. That is +2.2% against its own 200-day average. It sits at 40% of a 52-week range of ₹1,000 to ₹1,323. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 13 straight weeks.

Today the stock is in a confirmed uptrend — week 3 of stage 2, confirmed. At ₹1,128 it trades +2.2% versus its 200-day average and sits at 40% of its 52-week range (₹1,000–₹1,323).

Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved +145% while the NIFTY 500 moved +249% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 13 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Jenburkt Pharmaceuticals Ltd trades at 13.2× P/E, mid-range by its own standards (43rd percentile). Its long-run median P/E is 13.8×, measured across 10.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 13.2× is mid-range by its own standards (43rd percentile), against a long-run median of 13.8× measured over 10.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Why the multiple sits where it does: over the past year annual EPS moved +8.4% against a −13.7% price move — earnings outran the price, pushing the multiple DOWN its own range.

The price move, decomposed: over 5y, of the +18.2%/yr price move, ~+19.0%/yr came from earnings growth and ~−0.8 pp from the multiple (roughly flat); over 10y, of the +11.4%/yr price move, ~+14.0%/yr came from earnings growth and ~−2.6 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.

What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.

At its price on 13 June 2026, Jenburkt Pharmaceuticals Ltd was priced for profit growth of about 5.9% a year. Profit itself has compounded 12.3% a year over the past 10 years. The market pays that at 13.2× P/E, the 43rd percentile of its own 10-year range.

What the two numbers say together. The multiple is unremarkable against its own past, and the growth the price is paying for is below what this company has actually delivered. Both readings sit on the same earnings, so they are one reading rather than two.

How to hold this number: it is a reading of one day's price, taken on 13 June 2026, not a running figure. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements. Every other number on this page is read off the live quote.

Stage: Consistent Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Jenburkt Pharmaceuticals Ltd reads as consistent on its fundamental arc. Consistent — revenue and profit growth have stayed positive through the window, with ROCE at 27.0% and holding. The read is built from 9 quarters across 3 curves, on partial evidence.

Why it matters: steady curves with healthy returns are the compounding setup — the risk is the price, not the business.

One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.

4-Factor Sector Score

49.7/100 — rank 6 of 10 in Pharma - Others · 78% evidence confidence

Jenburkt Pharmaceuticals Ltd scores 49.7 out of 100 against the 10 companies it is compared with in Pharma - Others, ranking 6. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 16.5 + 19.1 + 10.1 + 4 = 49.7. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Jenburkt Pharmaceuticals Ltd reported ₹45.0 Cr of revenue in the Mar 26 quarter, +9.8% year on year. That is the 9th straight quarter of year-on-year growth. Over 10 years it has compounded at 6.0% a year. The last full year, FY26, came in at ₹169 Cr. The last four reported quarters add to ₹170 Cr.

FY26 revenue came in at ₹169 Cr (+11.2% on the year), capping 10 years at 6.0% compound. The latest quarter (Mar 26) printed ₹45.0 Cr, +9.8% year on year — the 9th consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +11.8% growth against the decade's 6.0% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +11.8% over the last 4 quarters against +9.4%/yr over the last 8 — stabilising; TTM profit +6.1% vs +18.3%/yr — rolling over.

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Jenburkt Pharmaceuticals Ltd's operating margin is 32.0% in the Mar 26 quarter, +6.0 percentage points against the same quarter a year ago. Across 12 fiscal years the operating margin has ranged 17.0% to 27.0%. The current quarter is running above every full year in that window.

The latest quarter's operating margin is 32.0%, +6.0 pp against the same quarter a year ago. Across 12 fiscal years the operating margin has ranged 17.0%–27.0%.

Why the margin moved: operating margin went +5.5 pp year on year while gross margin went −0.2 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Jenburkt Pharmaceuticals Ltd earned ₹11.0 Cr of net profit in the Mar 26 quarter, +22.2% year on year. Full-year FY26 profit was ₹35.0 Cr. The 10-year compound rate is 12.3%. That is 24.4% of the quarter's revenue. The same quarter a year earlier earned ₹9.0 Cr.

Mar 26 profit was ₹11.0 Cr, +22.2% year on year. On the full year, FY26 printed ₹35.0 Cr (+9.4%), and the 10-year compound rate is 12.3%.

Why profit moved: revenue contributed +9.8% and the margin +6.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.

Pace comparison, last four quarters: profit +5.5% vs revenue +11.8%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 68% of Jenburkt Pharmaceuticals Ltd's reported profit arrived as operating cash — most of the profit is real cash. In FY26 that was ₹27.0 Cr of operating cash against ₹35.0 Cr of profit. After ₹13.0 Cr of capital spending, ₹14.0 Cr was left as free cash.

FY26: operating cash of ₹27.0 Cr against reported profit of ₹35.0 Cr, leaving free cash of ₹14.0 Cr after ₹13.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 68% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

🚨 Why conversion sits at 68%: the cash cycle stretched 32 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.

Router verdict: conversion is below par and the cash cycle has stretched 32 days — the next section's job is to find where the cash is stuck.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Jenburkt Pharmaceuticals Ltd's cash conversion cycle runs 115 days in FY26, up from 83 days in FY21. Capital spending ran ₹62.0 Cr over the last 3 years. At FY26 sales of ₹169 Cr each day of that cycle holds about ₹0.5 Cr, so roughly ₹53.0 Cr sits inside the business at any moment.

FY26: debtors at 53 days, inventory at 154 days — roughly 5.1 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 115 days, looser than FY21's 83.

The full loop: cash goes out to suppliers and production on day 0; stock waits 154 days to sell; customers pay about 53 days after that; and suppliers themselves are paid at 91 days — netting out to the 115-day cycle.

In money terms: at FY26 sales of ₹169 Cr, each day of the cycle holds about ₹0.5 Cr — so the 115-day loop keeps roughly ₹53.0 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹62.0 Cr over the last 3 fiscal years against ₹8.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹46.0 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Jenburkt Pharmaceuticals Ltd earns a ROCE of 27% in FY26. That is up from a trough of 24% in FY21. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 20.7% net margin on 0.75× asset turns.

FY26 ROCE is 27%, recovered from a FY21 trough of 24% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY26): 20.7% net margin × 0.75× asset turns × 1.15× balance-sheet leverage ≈ 17.9% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.

Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.

Jenburkt Pharmaceuticals Ltd carries ₹2.0 Cr of borrowings against ₹197 Cr of equity in FY26, a debt-to-equity of 0.01. Over 5 years borrowings went from ₹5.0 Cr to ₹2.0 Cr. Capital spending ran ₹62.0 Cr across the last 3 of those years.

FY26: borrowings of ₹2.0 Cr against equity of ₹197 Cr — a debt-to-equity of 0.01. Over 5 years borrowings went from ₹5.0 Cr to ₹2.0 Cr while capital spending ran ₹62.0 Cr in just the last 3 — the build-out is being paid for out of cash, not debt.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

No holder of Jenburkt Pharmaceuticals Ltd moved a full percentage point over the last two years — the register is quiet. Domestic institutions moved +0.1 points over the same window, to 0.1%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Promoters: −0.6 points over 8 quarters to 46.6%; Domestic institutions: +0.1 points over 8 quarters to 0.1%; Foreign institutions: +0.0 points over 8 quarters to 0.0%.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Jenburkt Pharmaceuticals Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Frequently asked questions